News about "Eli Lilly"

Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study

Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.

Eli Lilly | 30/03/2026 | By News Bureau

Eli Lilly Eyes USD 2 Billion AI Drug Discovery Deal with Insilico Medicine

Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.

Eli Lilly | 30/03/2026 | By Darshana

Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial

Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.

Eli Lilly | 20/03/2026 | By News Bureau

EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis

In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.

Eli Lilly | 17/03/2026 | By Akanki

Eli Lilly Commits USD 3 Billion To Expand China Manufacturing

Eli Lilly and Company plans to invest USD 3 billion in China over the next decade to expand its local manufacturing and supply chain capabilities as it prepares for potential demand for new diabetes and obesity treatments.

Eli Lilly | 12/03/2026 | By Darshana |  104

Eli Lilly Enters USD 1.12 Billion Gene-Editing Partnership with Seamless Therapeutics

Eli Lilly and Company has entered into a strategic collaboration worth up to USD 1.12 billion with private gene-editing company Seamless Therapeutics to develop next-generation therapies for hearing loss. The agreement strengthens Lilly’s push into genetic medicines and expands its pipeline beyond its core diabetes and obesity treatments.

Eli Lilly | 29/01/2026 | By Darshana |  176

Innovation Led Growth Dominates Indian Pharma Market in 2025

The India’s pharmaceutical market grew 10.6 percent year-on-year in December 2025, driven by chronic therapies, GLP-1 drugs, and strong innovation-led demand.

Eli Lilly | 15/01/2026 | By News Bureau |  694

ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly

ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.

Eli Lilly | 29/12/2025 | By Darshana |  202

Eli Lilly Expands USA Manufacturing with Alabama Plant

The site will focus on producing synthetic and peptide-based medicines, including Lilly’s first oral GLP-1 weight-loss therapy, Orforglipron, which the company expects to submit for regulatory approval early next year.

Eli Lilly | 11/12/2025 | By Darshana |  108

FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL

Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.

Eli Lilly | 04/12/2025 | By Dineshwori |  177